NEW YORK ( TheStreet) -- Mallinckrodt, the 145-year-old pharmaceutical company, continues to grow. Mark Trudeau, the company's CEO, told TheStreet's Debra Borchardt that won't change any time soon.The company is expected to be spun off from Covidien (COV) this year.
Quick Take: Mallinckrodt Feeling No Pain
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts